661 related articles for article (PubMed ID: 15018591)
1. Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.
Blondeau JM
Drugs; 2004; 64(6):611-28. PubMed ID: 15018591
[TBL] [Abstract][Full Text] [Related]
2. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.
Talan DA; Naber KG; Palou J; Elkharrat D
Int J Antimicrob Agents; 2004 Mar; 23 Suppl 1():S54-66. PubMed ID: 15037329
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.
Waugh J; Keating GM
Drugs Aging; 2004; 21(1):55-64; discussion 65-6. PubMed ID: 14715044
[TBL] [Abstract][Full Text] [Related]
4. The treatment of urinary tract infections and use of ciprofloxacin extended release.
Hickerson AD; Carson CC
Expert Opin Investig Drugs; 2006 May; 15(5):519-32. PubMed ID: 16634690
[TBL] [Abstract][Full Text] [Related]
5. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
Carson C; Naber KG
Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
[TBL] [Abstract][Full Text] [Related]
6. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.
Henry DC; Bettis RB; Riffer E; Haverstock DC; Kowalsky SF; Manning K; Hamed KA; Church DA
Clin Ther; 2002 Dec; 24(12):2088-104. PubMed ID: 12581547
[TBL] [Abstract][Full Text] [Related]
7. Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
Talan DA; Klimberg IW; Nicolle LE; Song J; Kowalsky SF; Church DA
J Urol; 2004 Feb; 171(2 Pt 1):734-9. PubMed ID: 14713799
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic Resistance Among Uropathogenic
Kot B
Pol J Microbiol; 2019 Dec; 68(4):403-415. PubMed ID: 31880885
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of fluoroquinolones.
Schaeffer AJ
Dis Mon; 2003 Feb; 49(2):129-47. PubMed ID: 12601342
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
Cox CE; Marbury TC; Pittman WG; Brown GL; Auerbach SM; Fox BC; Yang JY
Clin Ther; 2002 Feb; 24(2):223-36. PubMed ID: 11911553
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women.
Garrison J; Hooton TM
Expert Opin Pharmacother; 2001 Aug; 2(8):1227-37. PubMed ID: 11584990
[TBL] [Abstract][Full Text] [Related]
13. Contemporary management of uncomplicated urinary tract infections.
Guay DR
Drugs; 2008; 68(9):1169-205. PubMed ID: 18547131
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ciprofloxacin XR 1000 mg once daily versus ciprofloxacin 500 mg twice daily in the treatment of complicated urinary tract infections.
Mirone V; Fusco F; Taglialatela D; Verze P; Di Vito C; Lotti T; Imbimbo C;
J Chemother; 2009 Dec; 21(6):651-60. PubMed ID: 20071289
[TBL] [Abstract][Full Text] [Related]
15. The expanding role of fluoroquinolones.
Schaeffer AJ
Am J Med; 2002 Jul; 113 Suppl 1A():45S-54S. PubMed ID: 12113871
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
18. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.
Miller LG; Tang AW
Mayo Clin Proc; 2004 Aug; 79(8):1048-53; quiz 1053-4. PubMed ID: 15301333
[TBL] [Abstract][Full Text] [Related]
19. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens.
Richard GA; Mathew CP; Kirstein JM; Orchard D; Yang JY
Urology; 2002 Mar; 59(3):334-9. PubMed ID: 11880065
[TBL] [Abstract][Full Text] [Related]
20. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
